Status
Conditions
Treatments
About
In Portugal, the prevalence of Fabry disease is largely unknown as recently has been stressed by the Portuguese hypertrophic cardiomyopathy registry investigators.
On the other hand, few data on Fabry screening protocols in patients with compromised ejection fraction including burned-out hypertrophic cardiomyopathy series have been published.
This project intends to perform screening of Fabry disease in patients with distinct cardiomyopathy phenotypes of unknown or dubious etiology and explore the less knew impact of the disease in other cardiac phenotypes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with heart disease diagnosed after the age of 30:
Exclusion criteria
600 participants in 4 patient groups
Loading...
Central trial contact
Elisabete Martins, MD, PhD; Janete Santos, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal